688189 Hunan Nucien Pharmaceutical Co., Ltd.
- 5.76
- -0.08-1.37%
Hunan Nucien Pharmaceutical Co., Ltd. News
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) has repurchased a cumulative total of 0.4479% of its shares.
On June 3rd, Gelunhui reported that as of May 31st, 2024, Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) had accumulated the repurchase of 1,228,955 shares of the company's stock through the Shanghai Stock Exchange trading system in a centralized auction trading manner, accounting for 0.4479% of the total share capital of the company of 274,400,000 shares. The highest transaction price of the repurchase was 9.24 yuan/share, the lowest was 5.45 yuan/share, and the total amount of funds paid was RMB 7,997,384.37 yuan (excluding transaction fees such as stamp duty and transaction commission).
Nanxin Pharmaceutical (688189.SH): The company did not repurchase shares in April
Gelonghui, May 7, 丨 Nanxin Pharmaceutical (688189.SH) announced that in April 2024, the company did not repurchase shares. As of April 30, 2024, the company has repurchased a total of 1,228,955 shares through the Shanghai Stock Exchange trading system, accounting for 0.4479% of the company's total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 5.45 yuan/share, and the total capital paid was RMB 7,997,384.37 (excluding transaction fees such as stamp duty and transaction commissions).
Nanxin Pharmaceutical (688189.SH) announced first-quarter results, net profit of 37.6665 million yuan, a decrease of 69.95%
Nanxin Pharmaceutical (688189.SH) released its report for the first quarter of 2024, achieving operating income of 1.1 during the reporting period...
Nanxin Pharmaceutical (688189.SH): Has repurchased a total of 1,229,000 company shares
Gelonghui, April 2, 丨 Nanxin Pharmaceutical (688189.SH) announced that as of March 31, 2024, the company had repurchased a total of 1,229,000 shares through the Shanghai Stock Exchange trading system, accounting for 0.4479% of the company's total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 5.45 yuan/share, and the total amount of capital paid was RMB 7,997,384.37 (excluding transaction fees such as stamp duty and transaction fees).
Nanxin Pharmaceutical (688189.SH) announced 2023 annual results with net profit of 3.7515 million yuan, turning a year-on-year loss into a profit
According to the Zhitong Finance App, Nanxin Pharmaceutical (688189.SH) disclosed its 2023 annual report. The company achieved revenue of 745 million yuan during the reporting period, an increase of 6.55% over the previous year. Net profit attributable to shareholders of listed companies was 3.7515 million yuan, and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 11.0774 million yuan, turning a loss into a profit over the previous year. Basic earnings per share were 0.0137 yuan/share. During the reporting period, due to factors such as respiratory diseases, especially influenza, several large-scale outbreaks during the year, the company's sales of antiviral drugs increased; at the same time, the company's sales volume of antiviral drugs increased; at the same time, according to external factors
Nanxin Pharmaceutical (688189.SH): A total cost of 7.936 million yuan to buy back 0.4449% of the shares
Gelonghui, March 1, 丨 Nanxin Pharmaceutical (688189.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,220,755 shares through the Shanghai Stock Exchange trading system, accounting for 0.4449% of the company's total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 5.45 yuan/share, and the total amount of capital paid was RMB 7,936,421.76.
Nanxin Pharmaceutical (688189.SH) Performance Report: 2023 net profit of 3,547,700 yuan reverses year-on-year losses
Gelonghui, Feb. 28, 丨 Nanxin Pharmaceutical (688189.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 744 million yuan, an increase of 6.50% over the same period of the previous year; achieved operating profit of 7.5947 million yuan, achieved a total profit of 6.9344 million yuan, and realized net profit attributable to shareholders of listed companies of 3,5477 million yuan, turning a loss into a profit over the previous year. As of December 31, 2023, the total assets of the company were 1725.985,500 yuan, a decrease of 11.66% over the same period last year; owners' equity attributable to the parent company was 1,317.912,200 yuan
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) May Have Run Too Fast Too Soon With Recent 29% Price Plummet
Hunan Nucien Pharmaceutical Co., Ltd. (SHSE:688189) shareholders that were waiting for something to happen have been dealt a blow with a 29% share price drop in the last month. Instead of being rew
Nanxin Pharmaceutical (688189.SH): A total of 246,700 shares have been repurchased as of January 31
Gelonghui, February 2, 丨 Nanxin Pharmaceutical (688189.SH) announced that as of January 31, 2024, the company had repurchased 246,709 shares of the company's shares through centralized bidding transactions, accounting for 0.0899% of the company's total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 7.30 yuan/share, and the total amount of capital paid was RMB 1,999,602.58 (excluding transaction fees such as stamp duty and transaction fees).
Nanxin Pharmaceutical (688189.SH): 2023 net profit pre-profit of 10 million yuan
Gelonghui, January 30丨Nanxin Pharmaceutical (688189.SH) announced the 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected that net profit attributable to owners of the parent company in 2023 will turn a loss into a profit compared with the same period last year, and achieve net profit attributable to the owners of the parent company of 200,000 yuan to 10 million yuan. The net profit attributable to the owners of the parent company after deducting non-recurring profit and loss for the year 2023 is expected to be -5 million yuan to 5 million yuan.
Yang Min, the core technician of Nanxin Pharmaceutical (688189.SH), retired
Nanxin Pharmaceutical (688189.SH) announced that Yang Min, the company's core technician, recently reached the legal retirement age,...
Nanxin Pharmaceutical (688189.SH): Initial repurchase of 65,000 shares
Gelonghui, January 12, 丨 Nanxin Pharmaceutical (688189.SH) announced that on January 12, 2024, the company repurchased 65,000 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0237% of the company's total share capital. The highest price of the repurchase transaction was 9.24 yuan/share, the lowest price was 9.10 yuan/share, and the total capital paid was RMB 595,212.34.
Nanxin Pharmaceutical (688189.SH): No share repurchase has been implemented
Gelonghui, January 3, 丨 Nanxin Pharmaceutical (688189.SH) announced that as of December 31, 2023, the company had not implemented a share repurchase.
Nucien Pharmaceutical to Repurchase Up to 10 Million Yuan Shares
Hunan Nucien Pharmaceutical (SHA:688189) plans to repurchase about 5 million yuan to 10 million yuan worth of shares via centralized bidding transactions. The Chinese drugmaker will buy back about 315
Nanxin Pharmaceutical (688189.SH): It is making every effort to promote and accelerate the research and development of the paramivir inhalation solution project
Gelonghui, December 13|Nanxin Pharmaceutical (688189.SH) said on the investor interactive platform that the company's drugs for influenza prevention include Liwei (paramivir sodium chloride injection) and Nanxin (oseltamivir phosphate dry suspension). Among them, Liwei (paramivir sodium chloride injection) can be used for all age groups, and Nanxin (oseltamivir phosphate dry suspension) can be used to prevent influenza A and B in people aged 1 year and above. The common symptoms of diseases caused by influenza, syncytial infection, and mycoplasma infections are fever, sore throat, etc., and the company's product Baostei (compound ibuprofen tablets) is OK
Nanxin Pharmaceutical (688189.SH): Product layout in the fields of colds, antiviral, cardiovascular and cerebrovascular is constantly being enriched
On November 21, Gelonghui, some investors asked Nanxin Pharmaceutical (688189.SH) on the investor interactive platform, “Could you tell me about the company's current production, operation and R&D situation?” The company said that the company arranges production according to customer orders and market demand, and production and operation are currently being carried out in an orderly manner. In terms of research and development, the company's oseltamivir phosphate dry suspensions, atorvastatin calcium tablets, and ibuprofen suspension drops obtained drug registration approval; benapril hydrochlorothiazide tablets and cefuroxime ester dispersions passed generic drug consistency evaluations; fexofenadine hydrochloride oral suspension submitted a marketing license application; class 1 intended for diabetic nephropathy treatment
[BT Financial Report Instantaneous Analysis] Nanxin Pharmaceutical's 2023 Three-Quarter Report: Market Recovery and Financial Performance Analysis Driven by R&D
Nanxin Pharmaceutical (stock code: 688189), as a company focusing on the R&D, production and sales of antiviral and infectious disease prevention drugs, showed significant progress in the gradual recovery of the market and product line enrichment in the third quarter of 2023. Although the COVID-19 pandemic has had an impact on market demand for the company's core products, the company's terminal market demand has increased with the liberalization of epidemic control and the increase in the level of influenza activity. In terms of assets and liabilities, the total assets of Nanxin Pharmaceutical decreased from 1,954 billion yuan at the end of the previous year to 1,677 billion yuan at the end of the reporting period, a decrease of 14.16%. liabilities
Nanxin Pharmaceutical (688189.SH) released the first three quarter results, net profit of 655,500 yuan, a year-on-year decrease of 95.52%
According to Zhitong Finance App, Nanxin Pharmaceutical (688189.SH) released its report for the first three quarters of 2023. The company's operating income was 562 million yuan, up 2.67% year on year; net profit attributable to shareholders of listed companies was 655,500 yuan, down 95.52% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 58637 million yuan, down 31.12% year on year; basic earnings per share of 0.0024 yuan/share.
High incidence recently! “Mycoplasma pneumonia” is frequently popular, and many companies respond to investors' questions
This year may be the year of the Mycoplasma pneumoniae epidemic
Nanxin Pharmaceutical (688189.SH): Production and sales of APIs related to GLP-1 peptides have not yet been involved
Glonghui, Oct. 11 | Nanxin Pharmaceutical (688189.SH) stated on the investor interactive platform that up to now, the company and its subsidiaries have not been involved in the production and sale of APIs related to GLP-1 peptides.
Analysis
Price Target
No Data
